STADA and SBP Group Formed Biosimilars Partnership
The collaboration targets the development and commercialization of a pembrolizumab biosimilar and other candidates.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Do you believe partnerships to produce more biosimilars help make healthcare more affordable?
STADA and SBP Group have formed a partnership to develop and supply biosimilar products, beginning with a pembrolizumab candidate. The agreement establishes a framework to expand the effort to three additional biosimilars across oncology and immunology.
Why it matters
The partnership combines regional marketing expertise with centralized manufacturing to increase the accessibility of complex biologic therapies. This development signals a strategic move to address high-demand treatments through the biosimilars market.
The agreement covers a pembrolizumab biosimilar, with plans to add three additional biosimilars across oncology and immunology. The scope of the partnership includes four total candidates in development.
The players
STADA
A pharmaceutical company that manages marketing and holds regulatory authorizations for medicines across Europe and the CIS.
SBP Group
A corporate entity operating through subsidiaries like CTTQ to manage drug development and manufacturing infrastructure.
CTTQ
A subsidiary of SBP Group responsible for the end-to-end development, manufacturing, and supply of biosimilar candidates.
The details
CTTQ, a subsidiary of SBP Group, serves as the development, manufacturing, and supply partner for the biosimilar candidates. STADA maintains the marketing authorizations and holds exclusive sales rights in the European Union, Switzerland, the United Kingdom, and the Commonwealth of Independent States. Biosimilars are highly similar versions of a biological medicine, which are large, complex molecules derived from living organisms that are usually expensive to produce.
Timeline
October 5, 2026: The partnership announcement was published.
The Tech Race
This partnership follows the broader trend of expanding market competition for established high-cost oncology biologics. It positions the companies to challenge existing market share in the EU and surrounding regions through the development of a pembrolizumab candidate.
The development of these biosimilars aims to expand therapeutic options for patients requiring oncology and immunology treatments. Availability and pricing remain unannounced as the products are in the development pipeline.
The takeaway
This agreement highlights the growing push for manufacturers to secure biosimilar portfolios in oncology. Investors and clinicians should monitor for future regulatory disclosures regarding the pembrolizumab development timeline.
Further reading
For more on how new manufacturing frameworks are affecting the market, visit our Biotech section.
Live Poll
Do you believe partnerships to produce more biosimilars help make healthcare more affordable?
